SAN DIEGO, Calif., March 11, 2020 /PRNewswire/ -- Amir Jafri, CEO of Immunicom, Inc., a medical technology company that has been awarded FDA Breakthrough Device Designation for its non-pharmaceutical solution for treating stage IV metastatic cancer, was one of five exclusively invited guest panelists at Congressman Dan Crenshaw's second annual Healthcare Innovation Summit held at Rice University. The summit showcased cutting-edge research that highly contribute to the continued growth of curing terminal diseases. Mr. Jafri spoke on Immunicom's pioneering approach that builds from research of esteemed scientists, such as Dr. James Allison, co-winner of the 2018 Nobel Prize in Physiology or Medicine for immunotherapy discoveries.
"It was an honor to host Mr. Jafri. He is an innovative entrepreneur whose idea behind Immunicom is creating a premier breakthrough technology in immunotherapy," said Texas Congressman Dan Crenshaw about the Fireside chat.
"Immunicom's ethos is not just about developing an effective solution to cancer. It's about helping that single mother who is diagnosed with breast cancer and is on Medicaid. It's about doing it in a way that everybody in the country can afford to receive the best therapies that are available," said Mr. Jafri when discussing the projected impact of Immunicom.
Congressman Crenshaw awarded Dr. Allison the Susan Crenshaw Congressional Healthcare Innovation Award, named after his late mother. This award is presented to those who dedicated their lives to healthcare innovations. "We are entering a period where we can think of curing the disease [of cancer]. I can say that with confidence… I think it's time for optimism, we know this can be done," said Dr. Allison in his Keynote speech.
For further recaps of the summit, go to www.Immunicom.com.
Immunicom, Inc. is a privately-held medical technology company located in San Diego, CA and Houston, TX focused on developing innovative, non-pharmaceutical approaches for treating cancer, inflammatory diseases, and autoimmune diseases. Immunicom's revolutionary blood-filtering technology has the potential to effectively treat a wide variety of cancer types including those that have not responded to other treatment strategies including other drug and biological-based immunotherapy options with possibly fewer side effects. The company seeks to leverage its technology to address unmet medical needs and improve patient access and affordability of cancer and other inflammatory and autoimmune disease treatments around the world.
This press release contains certain forward-looking statements regarding Immunicom products, technological capabilities, and future business aspirations. All such statements are based upon current Immunicom expectations and involve a number of business and technical risks and uncertainties that could cause actual results to differ materially from anticipated results described, implied or projected in any forward-looking statement, including, without limitation, clinical trial results, regulatory approvals, unexpected changes in technologies, uncertainties inherent in product development and commercialization, intellectual property protection, and the ability of our products to gain market acceptance.
For Additional Information Contact:
Chief Commercial Officer
SOURCE Immunicom, Inc.